Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Capecitabine in Adjuvant Colon Cancer
NCT02581423Phase 4Completed
- Sponsor
- Roche
- Start
- Aug 2005
- Primary completion
- Mar 2007
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of capecitabine in colon cancer, sponsored by Roche. Primary endpoints: Incidence of adverse events (AEs) at 6 months and Incidence of treatment discontinuation due to AEs at 6 months. Started Aug 2005; status: completed.
02
Drugs
capecitabine
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT02581423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02581423.